Literature DB >> 33830901

Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.

Alexandra Rockstroh1, Johannes Wolf2,3, Jasmin Fertey1, Sven Kalbitz4, Stefanie Schroth4, Christoph Lübbert4,5,6, Sebastian Ulbert1, Stephan Borte2,3.   

Abstract

Monitoring the humoral protective immune response and its durability after SARS-CoV-2 infections is essential for risk assessment of reinfections, the improvement of diagnostic methods and the evaluation of vaccine trials. We have analyzed neutralizing antibodies and IgG responses specific to different antigens, including the inactivated whole-virion of SARS-CoV-2, the spike subunit 1 protein and its receptor binding domain, as well as the nucleocapsid protein. We show the dynamic developments of the responses from the early convalescent stages up to 9 months post symptoms onset in follow-up samples from 57 COVID-19 patients with varying clinical severity. By correlating antibody signals to neutralizing titers, valid diagnostic markers for the estimation of neutralizing protection could be identified.

Entities:  

Keywords:  COVID-19; Nucleocapsid-ELISA; RBD-ELISA; S1-ELISA; humoral immunity; inactivated SARS-CoV-2; neutralizing antibodies

Year:  2021        PMID: 33830901     DOI: 10.1080/22221751.2021.1913973

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  18 in total

1.  Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.

Authors:  Charles F Schuler; Carmen Gherasim; Kelly O'Shea; David M Manthei; Jesse Chen; Cristyn Zettel; Jonathan P Troost; Andrew A Kennedy; Andrew W Tai; Donald A Giacherio; Riccardo Valdez; James L Baldwin; James R Baker
Journal:  Microbiol Spectr       Date:  2021-09-01

2.  Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial.

Authors:  Pedro Gutiérrez-Castrellón; Tania Gandara-Martí; Ana T Abreu Y Abreu; Cesar D Nieto-Rufino; Eduardo López-Orduña; Irma Jiménez-Escobar; Carlos Jiménez-Gutiérrez; Gabriel López-Velazquez; Jordi Espadaler-Mazo
Journal:  Gut Microbes       Date:  2022 Jan-Dec

3.  A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum.

Authors:  Syed Hani Abidi; Kehkashan Imtiaz; Akbar Kanji; Shama Qaiser; Erum Khan; Kiran Iqbal; Marc Veldhoen; Kulsoom Ghias; J Pedro Simas; Zahra Hasan
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

4.  Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.

Authors:  Javier Castillo-Olivares; David A Wells; Matteo Ferrari; Andrew C Y Chan; Peter Smith; Angalee Nadesalingam; Minna Paloniemi; George W Carnell; Luis Ohlendorf; Diego Cantoni; Martin Mayora-Neto; Phil Palmer; Paul Tonks; Nigel J Temperton; David Peterhoff; Patrick Neckermann; Ralf Wagner; Rainer Doffinger; Sarah Kempster; Ashley D Otter; Amanda Semper; Tim Brooks; Anna Albecka; Leo C James; Mark Page; Wilhelm Schwaeble; Helen Baxendale; Jonathan L Heeney
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

5.  Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.

Authors:  Margherita Rosati; Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Mahesh Agarwal; Jenifer Bear; Robert Burns; Xintao Hu; Eleni Korompoki; Duncan Donohue; David J Venzon; Meletios-Athanasios Dimopoulos; George N Pavlakis; Barbara K Felber
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

6.  Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD.

Authors:  Denis E Kolesov; Maria V Sinegubova; Lutsia K Dayanova; Inna V Dolzhikova; Ivan I Vorobiev; Nadezhda A Orlova
Journal:  Diagnostics (Basel)       Date:  2022-02-03

7.  Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.

Authors:  Maik Friedrich; Gabriele Pfeifer; Stefanie Binder; Achim Aigner; Philippe Vollmer Barbosa; Gustavo R Makert; Jasmin Fertey; Sebastian Ulbert; Jochen Bodem; Eva-Maria König; Nina Geiger; Axel Schambach; Erik Schilling; Tilo Buschmann; Sunna Hauschildt; Ulrike Koehl; Katherina Sewald
Journal:  Front Bioeng Biotechnol       Date:  2022-03-02

Review 8.  A look into the future of the COVID-19 pandemic in Europe: an expert consultation.

Authors:  Emil Nafis Iftekhar; Viola Priesemann; Rudi Balling; Simon Bauer; Philippe Beutels; André Calero Valdez; Sarah Cuschieri; Thomas Czypionka; Uga Dumpis; Enrico Glaab; Eva Grill; Claudia Hanson; Pirta Hotulainen; Peter Klimek; Mirjam Kretzschmar; Tyll Krüger; Jenny Krutzinna; Nicola Low; Helena Machado; Carlos Martins; Martin McKee; Sebastian Bernd Mohr; Armin Nassehi; Matjaž Perc; Elena Petelos; Martyn Pickersgill; Barbara Prainsack; Joacim Rocklöv; Eva Schernhammer; Anthony Staines; Ewa Szczurek; Sotirios Tsiodras; Steven Van Gucht; Peter Willeit
Journal:  Lancet Reg Health Eur       Date:  2021-07-30

Review 9.  Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2.

Authors:  Reginald M Gorczynski; Robyn A Lindley; Edward J Steele; Nalin Chandra Wickramasinghe
Journal:  J Pers Med       Date:  2021-11-25

10.  Evaluation of Simple Lateral Flow Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies.

Authors:  Olaf Nickel; Alexandra Rockstroh; Stephan Borte; Johannes Wolf
Journal:  Vaccines (Basel)       Date:  2022-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.